Skip to main content

Accelr8 Faces Delisting from NYSE Alternext

NEW YORK (GenomeWeb News) — Accelr8 said today that it has received notice from the NYSE Alternext that it is not in compliance with certain listing standards concerning its amount of stockholder equity, and that it must submit and implement a plan to regain compliance within 18 months.

The company said it is not in compliance with a section of the NYSE Alternext’s listing standards because it holds stockholder equity of less than $6 million and it has had losses from continuing operations and net losses in its five most recent fiscal years.

According to Accelr8, it will have until Feb. 6 to draft a plan to regain compliance, and it will have until July 6, 2010, to implement that plan. In the interim, the company will be subject to periodic review to determine its progress.

The company said it has informed NYSE Alternext that it intends to submit a plan in a timely fashion to resolve its listing deficiencies and regain compliance.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.